Table 2.
Proportions of bevacizumab-treated patients who received laser therapy or intravitreal triamcinolone, by diagnosis group and cohort
| Index cohort, % | BRVO
|
CRVO
|
DME
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| All | Before first bevacizumaba | After first bevacizumabb | All | Before first bevacizumaba | After first bevacizumabb | All | Before first bevacizumaba | After first bevacizumabb | |
| 2008c | n=148 | n=120 | n=338 | ||||||
| Laser or IVTA | 46.6 | 16.2 | 30.4 | 26.6 | 8.3 | 18.3 | 61.0 | 31.4 | 29.6 |
| Laser | 39.9 | 13.5 | 26.4 | 4.2 | 0 | 4.2 | 53.2 | 27.5 | 25.7 |
| IVTA | 14.9 | 2.7 | 12.2 | 24.1 | 8.3 | 15.8 | 21.3 | 6.8 | 14.5 |
| 2009c | n=221 | n=172 | n=560 | ||||||
| Laser or IVTA | 53.8 | 10.4 | 43.4 | 16.3 | 4.7 | 11.6 | 66.4 | 30.5 | 35.9 |
| Laser | 46.2 | 7.7 | 38.5 | 4.1 | 1.2 | 2.9 | 59.3 | 27.5 | 31.8 |
| IVTA | 14.0 | 3.6 | 10.4 | 13.4 | 3.5 | 9.9 | 21.3 | 5.9 | 15.4 |
| 2010c | n=306 | n=188 | n=1,009 | ||||||
| Laser or IVTA | 36.6 | 6.9 | 29.7 | 15.4 | 3.7 | 11.7 | 58.5 | 27.4 | 31.1 |
| Laser | 32.7 | 5.6 | 27.1 | 2.1 | 0 | 2.1 | 53.1 | 25.2 | 27.9 |
| IVTA | 7.2 | 2.0 | 5.2 | 11.7 | 3.7 | 8.0 | 15.3 | 4.2 | 11.1 |
| 2011 Jan–Jund | n=210 | n=131 | n=826 | ||||||
| Laser or IVTA | – | 6.7 | – | – | 1.5 | – | – | 18.8 | – |
| Laser | – | 5.2 | – | – | 0 | – | – | 17.8 | – |
| IVTA | – | 1.4 | – | – | 1.5 | – | – | 1.5 | – |
Notes:
a
Proportion of patients who received laser or ITVA before the first bevacizumab injection
b
proportion of patients who added or switched to laser or IVTA at the same time or after the first bevacizumab injection
c
these were indexed (time of the first anti-VEGF injection) from January 1 to December 31 of the calendar year and followed for 12 months
d
this cohort was indexed during January 1 to June 30, 2011 and followed for 6 months. En dashes denote no data.
Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; DME, diabetic macular edema; IVTA, intravitreal triamcinolone.